Abstract:Trial design: This was a phase III, randomized withdrawal, double-blind, placebo-controlled, enriched enrollment, parallel-group, multicenter study intended to demonstrate the safety, tolerability, and analgesic efficacy of oxycodone DETERx® (Xtampza™ ER) compared with matching placebo. Methods: This post hoc analysis was performed using data from a subpopulation of enrolled patients who were ≥65 years of age. The study enrolled male and female patients with a clinical diagnosis of moderate-to-severe chronic low back pain for a minimum of 6 months prior to screening who required around-the-clock opioid therapy. To be eligible for enrollment, patients were required to have an average 24-h pain intensity score of ≥5 and ≤9 on an 11-point (0-10) Pain Intensity-Numerical Rating Scale at the screening visit. The study enrolled both opioid-experienced and opioid-naïve patients. The study consisted of an open-label titration phase followed by a 12-week double-blind maintenance phase. The dose range was 40-160 mg oxycodone hydrochloride equivalent per day. This post hoc analysis evaluated the safety, tolerability, and effectiveness of oxycodone DETERx among patients ≥65 years of age. The effectiveness of oxycodone DETERx was evaluated based on average pain intensity scores, Patient Global Impression of Change, responder analysis, and Kaplan-Meier survival analysis. The safety and tolerability of oxycodone DETERx were also evaluated. Patients were randomized to either oxycodone DETERx or placebo using a blocked randomization scheme in a 1:1 ratio. Randomization was stratified by previous opioid use (naïve or experienced). The study drug was coded in a manner that maintained the blinding. Study personnel and patients remained blinded to the assigned treatments throughout the study. Results: For this post-hoc analysis, the intent-to-treat and randomized safety populations included 52 patients ≥65 years old, 26 each in the oxycodone DETERx and placebo groups, who participated in the study during the titration phase and were randomized to the double-blind maintenance phase. Clinically important pain reduction from screening was achieved with oxycodone DETERx, with the median pain intensity score decreasing from 7.50 at screening to 2.69 at Week 12. A clinically meaningful treatment difference of -0.9 in pain score between oxycodone DETERx and placebo was observed. All 18 elderly patients who completed the study reported improvement in pain, with 62% showing ≥30% improvement and 54% showing ≥50% improvement in pain intensity compared with patients on placebo (p = 0.0128 and p = 0.0501, respectively). Patients on oxycodone DETERx remained in the study longer than those on placebo. Of the 26 patients ≥65 years old randomized to continue oxycodone DETERx during the double-blind maintenance phase, 18 (69%) completed the study; only two patients (8%) in the oxycodone DETERx group discontinued due to adverse events. The safety and tolerability profiles showed no new or unexpected safety concerns. The adverse event profiles were similar between the titration and double-blind maintenance phases. Conclusions: Oxycodone DETERx was efficacious and generally well tolerated in patients ≥65 years old. Trial registration: The study was registered with ClinicalTrials.gov (NCT01685684).

Efficacy of Oxycodone-Acetaminophen Tablet in Treating Severe Back Pain in Orthopedics

Analgesic effect of parecoxib sodium and oxycodone for postoperative pain after total knee arthroplasty

Paracetamol and tramadol tablets in treatment of 1683 patients with moderate-to-sever pain in orthopedic outpatient and emergency

Evaluation on postoperative analgesia efficacy of oxycodone combined with dexmedetomidine in patients underwent laparoscopic radical surgery of colon cancer

THE EFFICACY AND SAFETY OF OXYCODONE HYDROCHLORIDE CONTROLLED-RELEASE TABLETS ON MANAGING ACUTE PAIN EPISODES IN PATIENTS WITH CHRONIC NECK PAIN

Analgesic Effect of Oxycodone and Acetaminophen Tablets for Total Hip Arthroplasty

The Efficacy of Oxycodone for Management of Acute Pain Episodes in Chronic Neck Pain Patients.

Efficacy of Paracetamol and Tramadol in the Treatment of Acute and Chronic Orthopedic Pain

Health Informatics of Oxycodone Hydrochloride Sustained-Release Tablets for Cancer Pain Treatment with Support of Computed Tomography Diagnosis

A retrospective analysis of the effects of different analgesics on the pain of patients with traumatic thoracolumbar fractures in the peri-treatment period

Analysis of Therapeutic Effects and Pharmacoeconomics of Oxycodone Acetaminophen Tablets and Morphine Sulfate Controlled-Release Tablets in the Treatment of Advanced Cancer Pain

Efficacy of Acetaminophen with and Without Oxycodone for Analgesia in Nonoperative Treatment of Extremity Fractures in Adults: Protocol for a Double-Blind Randomized Clinical Trial

Clinical observation of oxycodone hydrochloride controlled-release tablet for moderate to severe cancer pain

Oxycodone and Acetaminophen Combined with Pregabalin in Treatment of 155 Case of Lumbar Disc Herniation

Efficacy and safety of intravenous acetaminophen (2 g/day) for reducing opioid consumption in Chinese adults after elective orthopedic surgery: A multicenter randomized controlled trial

The effect of oxycodone on postoperative acute pain in patients undergoing thoracoscopic surgery

The observation of curative effect of oxycodone hydrochloride controlled-release tablets in management of moderate and severe cancer pain

Efficacy of anus plugging with oxycodone-acetaminophen tablets in the treatment of moderate and serious cancer pain

Clinical Observation of Oxycodone Hydrochloride Controlled-release Tablets in the Treatment of Moderate to Severe Cancer Pain

Observation of the Curative Effects of Oxycodone Hydrochloride Controlled-release Tablets for Moderate to Severe Cancer Pain

Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial